Tirzepatide vs. Retatrutide
Head-to-head comparison based on the profiles in the PepCycle library.
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Class | Metabolic | Metabolic |
| Description | A dual GIP/GLP-1 receptor agonist providing superior glycemic control and weight loss. | Triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors for enhanced weight loss and metabolic improvements. |
| Dose in studies | 2.5-15 mg weekly (titrate up slowly) | 1-12 mg weekly (titrate up slowly) |
| Frequency | Once weekly, same day each week | Once weekly |
| Half-life | 5 days | 6 days |
| Cycle length | Continuous under medical supervision | Continuous under medical supervision |
| Research level | 5/5 – Extensively researched | 4/5 – Well researched |
Tirzepatide: full profile · Retatrutide: full profile
Values from research literature – not medical advice.